Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.

The transaction builds upon a drug target discovery and validation partnership that first commenced between the two companies in 2018.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Financial terms include potential payments tied to the achievement of specified research, development, regulatory, and commercial milestones.

In addition to milestone payments, the agreement involves tiered royalties on future net sales of any therapeutic products resulting from the partnership.

The renewed collaboration focuses on applying human genetics to discover and validate new drug targets and assist with biomarker selection for precision medicines.

Researchers from Vertex Pharmaceuticals and Genomics will continue working closely together to integrate human genetic variation into research and development, aiming to better understand disease mechanisms where substantial unmet patient needs remain.

Vertex Pharmaceuticals executive vice-president and chief scientific officer Mark Bunnage said: “A deep understanding of human genetics and the underlying causal biology of diseases is foundational to how we discover and develop transformational therapies at Vertex.

“Over nearly a decade together, Genomics has proven to be an exceptional partner, combining sophisticated data science with deep genetic insights, and I’m delighted to be extending our productive partnership.”

Genomics is a transatlantic company founded in 2014 as a spin-out from the University of Oxford. Over the past decade, the business has collected, harmonised, and quality-controlled a large human genotype-phenotype database.

Genomics co-founder and CEO professor Peter Donnelly said: “Our unique platform and our proprietary algorithms allow us to bring the full power of human genetics to understand key biological processes driving disease and to use those insights to find novel targets and powerful biomarkers.” 

In July this year, Vertex signed a definitive agreement to purchase Crinetics Pharmaceuticals in a transaction valued at nearly $10bn.